Setmelanotide (Imcivree, Rhythm Pharmaceuticals) has a marketing authorisation for the 'treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above'.
The dosage schedule is available in the summary of product characteristics for setmelanotide.
The list price of setmelanotide is £2,376.00 per 10 mg per ml vial for injection (excluding VAT; company's evidence submission). The company has a commercial arrangement. This makes setmelanotide available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.